Article
Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?
Clinical pharmacology and therapeutics - 1 Jun 2010
van Gelder T, Hesselink D A
Abstract excerpt
Tacrolimus, widely used to prevent acute rejection following solid-organ transplantation, has become the cornerstone of immunosuppressive therapy after kidney transplantation. More than 70% of all renal transplant recipients receive this remarkably effective agent.(1) But tacrolimus is also highly toxic, and there is great between-patient variability in its pharmacokinetics. This, combined with a low therapeutic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.